Niagen Bioscience, Inc. — Director's Dealing 2025

Feb 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2025-02-25

Reporting Person: Fried Robert N (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-25	Performance Stock Unit	$	A	1518600	Acquired	2032-02-25	Common Stock (1518600)	Direct

Footnotes

F1: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the company's common stock when vested. The PSUs vest incrementally upon the Company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and subject to a change in control.